![TOP GLOVE CORPORATION BHD (SGX:BVA) | SGinvestors.io](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjPxvoDKt2K7jvt_q2JlCYAFRKp4ctmiwg5BShDNdk2H9kbuWStEhHMmG_W8foYKNAJmzd0XF3v2K-PyQeCDfLrhKqYMRObR5eh7p3SGI19FqV_oPSG93GqU5SWLNg6ugvyI9MSICk7eyyt/s1600/Top+Glove+Corporation.png)
Top Glove - Diversified Portfolio
But earnings recovery priced in; maintain HOLD
- Despite its more diversified glove portfolio, TOP GLOVE CORPORATION BHD (SGX:BVA) was similarly affected by stiff competition in 1HCY19. Although we expect earnings to improve with a pick-up in demand for its nitrile medical gloves, our earnings forecasts already impute a strong earnings recovery.
- Maintain HOLD and Target Price of MYR4.85, at 26x CY20E P/E or a 10% discount to our target for Hartalega in view of its lower margins/ROEs.
- Prefer Kossan in the sector (BUY, Target Price MYR5.10) for its exposure in the non-medical segment and undemanding valuation.
Affected by competition in 1HCY19
- We estimate that rubber medical gloves account for 85% of its sales volume. They are followed by plastic gloves, at 9%. Plastic gloves are facing a structural decline while rubber non-medical-glove sales, at 6% of its sales volume, are rising.
- Though non-medical gloves cushioned its earnings from weakness in other segments in 1HCY19, we believe a spike in latex costs affected its earnings.
Strong demand for its nitrile medical gloves
- Reflecting a pick-up in global glove purchases, the sales lead time for its nitrile medical gloves has risen to 50-60 days from 30-45. We believe global demand has picked up after purchasers’ minimal purchases in 1HCY19 amid trade-war uncertainties. Now that the US has implemented import tariffs on all of China’s gloves (except surgical gloves), we think importers are more certain of their total purchase costs.
Better q-o-q but weaker y-o-y 4Q
- 4QFY8/19 results are scheduled for release on 26 Sep. We expect net profit to be better q-o-q but weaker y-o-y (3QFY19: MYR75m, 4QFY18: MYR102m). We think there could be volume growth, driven by new capacity from F32 (Phase1) and F33, which will raise its total capacity by 6% upon full commencement.
- Margins may also improve q-o-q from higher latex glove ASPs and lower latex costs.
Lee Yen Ling
Maybank Kim Eng Research
|
https://www.maybank-ke.com.sg/
2019-09-24
SGX Stock
Analyst Report
4.850
SAME
4.850